226 related articles for article (PubMed ID: 31775036)
1. MLL1 Inhibition and Vitamin D Signaling Cooperate to Facilitate the Expanded Pluripotency State.
Zhang H; Khoa LTP; Mao F; Xu H; Zhou B; Han Y; O'Leary M; Nusrat A; Wang L; Saunders TL; Dou Y
Cell Rep; 2019 Nov; 29(9):2659-2671.e6. PubMed ID: 31775036
[TBL] [Abstract][Full Text] [Related]
2. MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency.
Zhang H; Gayen S; Xiong J; Zhou B; Shanmugam AK; Sun Y; Karatas H; Liu L; Rao RC; Wang S; Nesvizhskii AI; Kalantry S; Dou Y
Cell Stem Cell; 2016 Apr; 18(4):481-94. PubMed ID: 26996599
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
Wang ZH; Li DD; Chen WL; You QD; Guo XK
Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892
[TBL] [Abstract][Full Text] [Related]
5. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
[TBL] [Abstract][Full Text] [Related]
8. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
[TBL] [Abstract][Full Text] [Related]
13. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
14. SETDB1-Mediated Cell Fate Transition between 2C-Like and Pluripotent States.
Wu K; Liu H; Wang Y; He J; Xu S; Chen Y; Kuang J; Liu J; Guo L; Li D; Shi R; Shen L; Wang Y; Zhang X; Wang J; Pei D; Chen J
Cell Rep; 2020 Jan; 30(1):25-36.e6. PubMed ID: 31914391
[TBL] [Abstract][Full Text] [Related]
15. Mixed-Lineage Leukemia 1 Inhibition Enhances the Differentiation Potential of Bovine Embryonic Stem Cells by Increasing H3K4 Mono-Methylation at Active Promoters.
Li C; Han X; Wang J; Liu F; Zhang Y; Li Z; Lu Z; Yue Y; Xiang J; Li X
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569280
[TBL] [Abstract][Full Text] [Related]
16. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
17. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Weirich S; Kudithipudi S; Jeltsch A
Mol Oncol; 2017 Apr; 11(4):373-387. PubMed ID: 28182322
[TBL] [Abstract][Full Text] [Related]
18. MLL1 is essential for the senescence-associated secretory phenotype.
Capell BC; Drake AM; Zhu J; Shah PP; Dou Z; Dorsey J; Simola DF; Donahue G; Sammons M; Rai TS; Natale C; Ridky TW; Adams PD; Berger SL
Genes Dev; 2016 Feb; 30(3):321-36. PubMed ID: 26833731
[TBL] [Abstract][Full Text] [Related]
19. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
20. MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
Han X; Xiang J; Li C; Wang J; Wang C; Zhang Y; Li Z; Lu Z; Yue Y; Li X
Theriogenology; 2020 Apr; 146():58-70. PubMed ID: 32059151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
